SCHEMBL4025211

SCHEMBL4025211

Cc1c(F)cccc1C1C(C(=O)c2ccccn2)CN(CC(N)=O)CC1C(=O)c1ccccn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
CTNNB1 P35222 1/20 0.37
WNT3A P56704 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP2D6 P10635 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
PKM P14618 1/20 0.34
AGTR1 P30556 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PRNP P04156 1/20 0.34
CD274 Q9NZQ7 1/20 0.33
DRD4 P21917 1/20 0.33
HTR1A P08908 1/20 0.33
HTR2A P28223 1/20 0.33
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025206 1.00 NPC1 (0.38) NPC1RAB9AMAPTCTNNB1WNT3A
SCHEMBL4023587 0.89 EED (0.41) NPC1RAB9AMAPTCTNNB1WNT3A
SCHEMBL4023583 0.89 EED (0.41) NPC1RAB9AMAPTCTNNB1WNT3A
SCHEMBL4019675 0.88 NPC1 (0.36) NPC1RAB9AMAPTCTNNB1WNT3A
SCHEMBL4019678 0.88 NPC1 (0.36) NPC1RAB9AMAPTCTNNB1WNT3A
SCHEMBL4021790 0.82 KDM4E (0.39) KMT2ACYP2D6TAAR1CD274CHRM4
SCHEMBL4021793 0.82 KDM4E (0.39) KMT2ACYP2D6TAAR1CD274CHRM4
SCHEMBL4749099 0.81 POLB (0.38) MEN1KMT2ACYP2D6TAAR1EED
SCHEMBL4749101 0.81 POLB (0.38) MEN1KMT2ACYP2D6TAAR1EED
SCHEMBL4019759 0.79 MEN1 (0.37) NPC1RAB9AMEN1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 NPC1 263/4885RAB9A 2228/4885MAPT 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.